FindTrial
Sign In

Evaluation of the effects and predictive factors of double dose of adalimumab for the patients with Crohn's disease

Evaluation of the effects and predictive factors of double dose of adalimumab for the patients with Crohn's disease - ADA2 study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022270
Enrollment
20
Registered
2016-07-01
Start date
2016-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

double dose of adalimumab

Sponsors

Saitama Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: loss of response of adalimumab

Exclusion criteria

Exclusion criteria: refractory patients for adalimumab

Design outcomes

Primary

MeasureTime frame
effective rates—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center Gastroenterology and Hepatology

skato@saitama-med.ac.jp0492283564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026